Defensin Peptides vs SkinMedica TNS®: An Honest Comparison
Both defensin-based and growth factor–based technologies are used in advanced skincare, but they represent fundamentally different approaches to supporting visible skin rejuvenation — with different ingredient origins, different molecular definitions, and different published evidence profiles.
Both technologies have published clinical evidence. Both are sold through dermatologists and medical spas. Both carry premium price points. So what actually separates them?
SkinMedica TNS® technology is built around human fibroblast conditioned media (HFCM). The primary active ingredient in TNS Recovery Complex is the mixture of growth factors, cytokines, proteins, and exosomes secreted by cultured human fibroblast cells. Published clinical research documents visible improvements in skin appearance with TNS products. TNS Advanced+ combines this with a second chamber of botanicals and peptides.
DefenAge Age-Repair Defensins® are built around two defined, lab-synthesized peptides. Alpha-Defensin 5 and Beta-Defensin 3 are bioidentical versions of molecules the human body naturally produces — fully synthetic, vegan, and free from any biological tissue origin. Four published peer-reviewed clinical studies document visible improvements across the face, eye area, body skin, and in post-procedure contexts.
Both approaches have real published evidence. The meaningful differences lie in ingredient origin, molecular definition, batch consistency, and price — and those differences are worth understanding clearly before choosing.
For foundational context on how defensin peptides differ from retinoid-based approaches, see Defensin Peptides vs Retinol — the starting point for understanding the defensin difference.
SkinMedica TNS products are derived from Human Fibroblast Conditioned Media — the byproduct of culturing human fibroblast cells in a laboratory setting. This is disclosed in SkinMedica's own ingredient lists and published materials. TNS Recovery Complex lists HFCM as its primary ingredient.
DefenAge's defensin peptides are fully lab-synthesized — not derived from human tissue, animal tissue, or cell culture byproducts of any kind. They are vegan, cruelty-free, and structurally identical to molecules the human body naturally produces.
This is not a judgment about SkinMedica's efficacy. It is a factual difference in ingredient origin that many consumers and providers consider relevant to their purchasing decisions.
DefenAge has four published peer-reviewed studies across three journals — including a multi-center, double-blind, vehicle-controlled trial (Taub et al, JDD 2018) — documenting statistically significant visible skin improvement. SkinMedica TNS products are also supported by published clinical data. The key distinctions are ingredient origin, molecular definition, batch consistency, and price point.
For consumers who want clinically documented visible improvement from fully synthetic, vegan ingredients — priced lower than SkinMedica's hero product — the published evidence for DefenAge is directly relevant to that choice.
Two patented, lab-synthesized bioidentical peptides — Alpha-Defensin 5 and Beta-Defensin 3. Fully synthetic, vegan, no human- or animal-derived material. Four published peer-reviewed clinical studies. Exclusive to DefenAge — no other brand can legally formulate or sell these molecules for topical use.
Human Fibroblast Conditioned Media (HFCM) — the growth factors, cytokines, proteins, and exosomes secreted by cultured human fibroblast cells. TNS Recovery Complex lists HFCM as its primary ingredient. TNS Advanced+ combines HFCM with a second chamber of botanicals and peptides. Owned by Allergan Aesthetics / AbbVie.
The Published Clinical Evidence — Study by Study
Both technologies have published clinical research. Here is what the peer-reviewed literature documents for each — with full citations.
Multi-center, double-blind, vehicle-controlled trial
In this published trial, participants using the DefenAge defensin regimen demonstrated statistically significant visible improvement in tone, texture, firmness, lines, and overall appearance versus vehicle control. Evaluation included clinical grading, histopathology, immunohistochemistry, photography, and ultrasound — a rigorous multi-method study design.
JDD 2018;17(4):426–441. PMID: 29601620
Periocular wrinkles — independent follow-up trial
An independent follow-up trial focused on periocular wrinkles in which participants demonstrated significant visible improvement with the enhanced-concentration defensin BioSerum versus control. Replication in a second independent published trial adds further support to the evidence base.
JDD 2023;22(9):874–880. PMID: 37683059
Eye cream trial — periocular rhytids
Published trial of the DefenAge 3D Eye Radiance Cream in which participants demonstrated visible improvement in periocular wrinkles and skin quality — extending the clinical evidence to a dedicated eye-area product with fully synthetic ingredients.
J Cosmet Dermatol. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
Body cream trial — skin composition
Published trial of the DefenAge 10 Luxe Hand and Body Cream in which participants demonstrated visible improvement in skin composition and quality — extending defensin clinical evidence to body skin.
J Cosmet Dermatol. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235
Microneedling with defensins vs microneedling with PRP — a published head-to-head comparison
In this published pilot study, participants in the microneedling combined with defensins group demonstrated greater visible improvement in that study setting compared to participants in the microneedling combined with PRP group. PRP is a platelet-derived biologic — the same category of human-derived material that defines TNS. This published comparison is directly relevant for anyone evaluating synthetic versus biologic-derived approaches to post-procedure skin support.
Facial Plast Surg Clin North Am. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
Defensins are also compared to other biological and growth factor-based technologies, including exosome-based skincare and SkinBetter Science® — each representing a different approach to visible skin renewal.
Key Differences at a Glance
| Category | DefenAge Age-Repair Defensins® | SkinMedica TNS® Technology |
|---|---|---|
| Ingredient origin | 100% lab-synthesized, vegan, no human- or animal-derived material | Human Fibroblast Conditioned Media — sourced from cultured human fibroblast cells |
| Molecular definition | Two defined peptides with known sequences and published mechanisms | A complex mixture of growth factors, cytokines, proteins, and exosomes — not individually characterized for contribution |
| Batch consistency | Identical batch to batch — synthetic peptides with fixed sequences and concentrations | Inherent biological variability — conditioned media composition depends on cell culture conditions, passage number, and processing |
| Published clinical trials | Four published peer-reviewed studies across face, eyes, body, and post-procedure contexts in three journals | Multiple published clinical studies on TNS products documenting visible improvement in lines, wrinkles, tone, and texture |
| Study methodology | Multi-center, double-blind, vehicle-controlled (Taub 2018) with histopathology and ultrasound evaluation | Published clinical evidence including a 24-week, 45-subject TNS Advanced+ study |
| Post-procedure comparison | Published pilot study in which defensins demonstrated greater visible improvement than PRP in that study setting (Duncan 2018) | Long-established track record in post-procedure use; widely recommended by dermatologists for procedure recovery |
| Peptide exclusivity | Patents on the molecules themselves — no other brand can legally replicate this technology | Patented process for culturing and harvesting HFCM — but human fibroblast conditioned media as an ingredient class is used by other brands |
| Retinoid alternative | In the Taub 2018 trial, the defensin regimen was well tolerated in study participants including those who had not completed retinoid regimens | Not positioned or studied as a retinoid alternative |
| Hero product price | $198 (8-in-1 BioSerum) | ~$295 (TNS Advanced+) — approximately $97 more per bottle |
Four Meaningful Differences Worth Understanding
Defined molecules vs a complex mixture
In the Taub et al 2018 trial, visible improvement can be attributed to two specific, named, patented peptides with published mechanisms. TNS delivers a complex mixture of proteins and growth factors — many not individually characterized. With defensins, the science of what is present in the formula is fully traceable. With conditioned media, the mixture is acknowledged to contain hundreds of biomolecules whose individual contributions are not defined.
Synthetic vs human-derived origin
Defensin peptides are fully lab-synthesized — structurally identical to molecules the body naturally produces, but manufactured without any human or animal source material. TNS is derived from cultured human fibroblast cells. For consumers and providers for whom ingredient origin matters — this is a straightforward and factual distinction that is worth knowing before choosing between the two.
Consistent vs inherently variable
Synthetic peptides are identical batch to batch — same molecules, same concentrations, reproducible formulation. Conditioned media is a biological product: its composition can vary depending on cell culture conditions, passage number, and processing. Biological variability is a fundamental property of cell-derived ingredients that synthetic peptides do not share, regardless of how well the manufacturing process is standardized.
Price point
At $198 for the 8-in-1 BioSerum, DefenAge is priced lower than SkinMedica TNS Advanced+ at approximately $295 — a difference of approximately $97 per bottle. Both are clinically studied premium skincare products. DefenAge's published evidence across four peer-reviewed studies is available at a lower price point than SkinMedica's comparable hero product.
The Retinoid Alternative Question
This is one of the most searched questions in advanced skincare — and where the Taub et al 2018 trial data is directly relevant.
Retinoids are associated with visible skin improvement but also with a well-documented tolerability profile — redness, peeling, sun sensitivity, and an adjustment period. People with sensitive skin, rosacea, or a compromised barrier often do not complete retinoid regimens.
In the Taub et al 2018 trial, the defensin regimen was well tolerated in study participants — including those who had not completed retinoid regimens. The 2023 Hartman et al trial independently documented similar tolerability findings.
SkinMedica TNS has not been studied or positioned as a retinoid alternative. Its published clinical evidence addresses visible anti-aging improvement in a standard dermatology context. For anyone specifically seeking a clinically studied daily alternative to retinoids, DefenAge has the most directly relevant published evidence — with fully synthetic, vegan ingredients.
DefenAge may be right for you if:
- Ingredient origin matters to you — you prefer fully synthetic, vegan formulas
- You want clinically studied visible improvement at a lower price point
- You want a retinoid alternative that was well tolerated in published clinical trials
- You want post-procedure support with a published comparison against a biologic
- You want patented molecules exclusive to one brand — technology no other brand can replicate
- You want batch-consistent results from a defined, reproducible formula
SkinMedica TNS may appeal to you if:
- You have an established routine with TNS and are satisfied with your results
- Your dermatologist has specifically recommended TNS for your skin goals
- You are comfortable with human-derived ingredients and value the broad-spectrum growth factor approach
- You want a technology with decades of market presence and a large installed provider network
SkinMedica TNS is a legitimate, well-studied technology with real published clinical evidence and a long track record in dermatology. Its results are not in question. What is worth knowing clearly and factually is that its primary active ingredient is derived from cultured human fibroblast cells, that its mixture of growth factors and proteins is not individually characterized, and that it is priced approximately $97 more per bottle than DefenAge's hero product.
DefenAge has four published peer-reviewed studies across three journals — including a multi-center, double-blind, vehicle-controlled trial — and a published head-to-head pilot study in which the defensin approach demonstrated greater visible improvement than a human-derived biologic in that study setting. Its ingredients are fully synthetic and vegan.
For a consumer making an informed choice, the published evidence and the ingredient facts provide a clear basis for comparison. Both technologies work. The question is which approach fits your values, your budget, and your skin goals.
What Dermatologists Have Said About Defensin Technology
"The science is remarkable. For patients who previously couldn't tolerate retinoids, the visible results I've seen with defensin technology have been genuinely impressive."
Amy Taub, MD Lead author, Taub et al JDD 2018; co-investigator, Hartman et al JDD 2023
"For patients with sensitive skin or rosacea who need effective anti-aging without retinol irritation, this is the alternative I reach for. It delivers visible results without the trade-offs."
Melda Isaac, MD Board-Certified Dermatologist, Washington DC
"Defensins represent a new era in skin rejuvenation. The approach is genuinely distinct from growth factors, retinoids, and standard peptide categories — it belongs in its own class."
Gregory Keller, MD Principal Investigator, Taub et al 2018; Berens et al 2020; Eggerstedt et al 2023
Frequently Asked Questions
Is DefenAge the same as SkinMedica TNS?
No — they represent fundamentally different approaches to skin rejuvenation. DefenAge uses two defined, lab-synthesized bioidentical peptides. SkinMedica TNS uses Human Fibroblast Conditioned Media — a complex mixture of growth factors, proteins, and exosomes derived from cultured human fibroblast cells. The ingredient origin, molecular definition, batch consistency, and price point are all materially different. Both technologies have published clinical evidence; the differences lie in how they work and where they come from.
What is Human Fibroblast Conditioned Media — and where does it come from?
Human Fibroblast Conditioned Media (HFCM) is the mixture of proteins, growth factors, cytokines, and exosomes secreted by human fibroblast cells during laboratory cell culture. SkinMedica's TNS technology uses fibroblasts cultured from human tissue. This is disclosed in SkinMedica's own ingredient documentation — TNS Recovery Complex lists HFCM as its primary ingredient. DefenAge's defensin peptides contain no human-derived material of any kind — they are fully lab-synthesized and vegan.
How do the clinical evidence bases compare?
Both technologies have published peer-reviewed clinical data. DefenAge has four published studies across three journals: two in the Journal of Drugs in Dermatology including a multi-center, double-blind, vehicle-controlled trial; one in the Journal of Cosmetic Dermatology on the eye cream; one in the Journal of Cosmetic Dermatology on the body cream; and a published pilot study in which the defensin approach demonstrated greater visible improvement than PRP in that study setting. SkinMedica has multiple published clinical studies on TNS products documenting visible improvement in lines, wrinkles, tone, and texture. Both brands have real published evidence; DefenAge's covers more product categories and contexts.
Can I use DefenAge instead of retinol?
DefenAge is used by dermatologists for patients who have not completed retinoid regimens. In the Taub et al 2018 multi-center, double-blind trial, the defensin regimen was well tolerated in study participants — including those who had not completed retinoid regimens — while demonstrating statistically significant visible skin improvement. The 2023 Hartman et al trial independently documented similar tolerability. SkinMedica TNS is not positioned or studied as a retinoid alternative.
Why does batch consistency matter in skincare?
Batch consistency determines whether the product you buy today contains the same active ingredients in the same concentrations as the product you bought previously. DefenAge's synthetic peptides are chemically defined — every bottle contains the same two molecules at the same concentrations. Conditioned media is a biological product whose composition can vary depending on cell culture conditions, passage number, and processing. SkinMedica standardizes its manufacturing process, but biological variability is a fundamental property of any cell-derived ingredient that synthetic peptides simply do not have.
How does the price compare?
DefenAge's 8-in-1 BioSerum is $198. SkinMedica TNS Advanced+ is priced at approximately $295 — a difference of approximately $97 per bottle. DefenAge is also priced lower than several other products in the medical-grade skincare category, including Augustinus Bader (~$300) and Plated (~$267).
How does DefenAge compare to SkinMedica in post-procedure contexts?
SkinMedica has a long and well-documented track record in post-procedure use and is widely recommended for recovery after laser treatments and peels. DefenAge also has published post-procedure evidence: in a published pilot study (Duncan, Facial Plastic Surgery Clinics of North America, 2018), participants in the microneedling combined with defensins group demonstrated greater visible improvement in that study setting than participants in the microneedling combined with PRP group. Both technologies have published evidence in post-procedure contexts; the difference is that DefenAge's includes a direct published comparison against a human-derived biologic.
Explore more comparisons
References & Further Reading
- Taub A, Bucay V, Keller G, Williams J, Mehregan D. "Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen." Journal of Drugs in Dermatology. 2018;17(4):426–441. PMID: 29601620
- Hartman N, Loyal J, Taub A, Fabi S. "Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles." Journal of Drugs in Dermatology. 2023;22(9):874–880. doi: 10.36849/JDD.7184. PMID: 37683059
- Berens AM, Ghazizadeh S. "Effect of defensins-containing eye cream on periocular rhytids and skin quality." Journal of Cosmetic Dermatology. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
- Eggerstedt M, Torres-Maldonado S, Danielian A, Hwang SHJ, Echanique KA. "Impact of defensins-containing body cream on skin composition." Journal of Cosmetic Dermatology. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235. PMCID: PMC10087582
- Duncan DI. "Microneedling with Biologicals: Advantages and Limitations." Facial Plastic Surgery Clinics of North America. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
- Takahashi M, Umehara Y, Yue H, et al. "The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway." Frontiers in Immunology. 2021;12:712781. doi: 10.3389/fimmu.2021.712781
- Shimizu Y, Nakamura K, Kikuchi M, et al. "Lower human defensin 5 in elderly people compared to middle-aged." GeroScience. 2022;44(2):997–1009. PMID: 34105106
- Grove GL, Kligman AM. "Age-associated changes in human epidermal cell renewal." Journal of Gerontology. 1983;38:137–142.
- DefenAge. "Peer-reviewed study confirming effectiveness of defensin-based BioSerum." View study summary
- DefenAge. "Physician testimonials and clinical perspectives." View testimonials
DefenAge products are cosmetic formulations intended to improve the appearance of the skin and are not intended to affect the structure or function of the body. This page is for cosmetic skincare education only and does not constitute medical advice. Physician quotes are sourced from publicly available DefenAge materials and used with permission. TNS® and SkinMedica® are registered trademarks of Allergan Aesthetics, an AbbVie company — referenced here for comparison purposes only. Age-Repair Defensins® and DefenAge® are trademarks of Progenitor Biologics, LLC. Product prices are approximate and subject to change. Technology comparisons are based on publicly available ingredient information and peer-reviewed literature at time of publication. DefenAge makes no claims regarding the efficacy of competitor technologies.